StockData
Elite Pharmaceuticals Inc logo

Elite Pharmaceuticals Inc (ELTP) stock

ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)

Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –

Elite Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Elite Pharmaceuticals's cash was $38.94M at Jun 30, 2026. For fiscal 2026 it was $29.80M, up 163.3% from the year before. Over ten years it grew 10.0% a year on average. The highest annual figure on record is $29.80M in fiscal 2026.

Annual cash

PeriodPeriod endValueChange
FY2026Mar 31, 2026$29.80M+163.3%
FY2025Mar 31, 2025$11.32M+59.2%
FY2024Mar 31, 2024$7.11M-9.3%
FY2023Mar 31, 2023$7.83M-8.2%
FY2022Mar 31, 2022$8.54M+167.3%
FY2021Mar 31, 2021$3.19M+107.8%
FY2020Mar 31, 2020$1.54M-42.6%
FY2019Mar 31, 2019$2.68M-64.7%
FY2018Mar 31, 2018$7.57M-31.1%
FY2017Mar 31, 2017$10.98M-4.6%
FY2016Mar 31, 2016$11.51M+54.2%
FY2015Mar 31, 2015$7.46M+7.5%
FY2014Mar 31, 2014$6.94M+1781.1%
FY2013Mar 31, 2013$369.02K-44.8%
FY2012Mar 31, 2012$668.41K-63.4%
FY2011Mar 31, 2011$1.83M+215.8%
FY2010Mar 31, 2010$578.19K–

Quarterly cash

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$38.94M+79.1%
Q4 FY2026CQ1 2026Mar 31, 2026$29.80M+163.3%
Q3 FY2026CQ4 2025Dec 31, 2025$21.09M+154.4%
Q2 FY2026CQ3 2025Sep 30, 2025$26.62M+178.6%
Q1 FY2026CQ2 2025Jun 30, 2025$21.74M+158.6%
Q4 FY2025CQ1 2025Mar 31, 2025$11.32M+59.2%
Q3 FY2025CQ4 2024Dec 31, 2024$8.29M+42.6%
Q2 FY2025CQ3 2024Sep 30, 2024$9.55M+10.4%
Q1 FY2025CQ2 2024Jun 30, 2024$8.41M-7.4%
Q4 FY2024CQ1 2024Mar 31, 2024$7.11M-9.3%
Q3 FY2024CQ4 2023Dec 31, 2023$5.82M-67.5%
Q2 FY2024CQ3 2023Sep 30, 2023$8.65M-53.4%
Q1 FY2024CQ2 2023Jun 30, 2023$9.08M-54.1%
Q4 FY2023CQ1 2023Mar 31, 2023$7.83M-8.2%
Q3 FY2023CQ4 2022Dec 31, 2022$17.91M+145.7%
Q2 FY2023CQ3 2022Sep 30, 2022$18.56M+313.2%
Q1 FY2023CQ2 2022Jun 30, 2022$19.78M+316.3%
Q4 FY2022CQ1 2022Mar 31, 2022$8.54M+167.3%
Q3 FY2022CQ4 2021Dec 31, 2021$7.29M+34.7%
Q2 FY2022CQ3 2021Sep 30, 2021$4.49M-5.9%
Q1 FY2022CQ2 2021Jun 30, 2021$4.75M+48.8%
Q4 FY2021CQ1 2021Mar 31, 2021$3.19M+107.8%
Q3 FY2021CQ4 2020Dec 31, 2020$5.41M+138.1%
Q2 FY2021CQ3 2020Sep 30, 2020$4.77M+79.5%
Q1 FY2021CQ2 2020Jun 30, 2020$3.19M+7.3%
Q4 FY2020CQ1 2020Mar 31, 2020$1.54M-42.6%
Q3 FY2020CQ4 2019Dec 31, 2019$2.27M-44.2%
Q2 FY2020CQ3 2019Sep 30, 2019$2.66M-47.9%
Q1 FY2020CQ2 2019Jun 30, 2019$2.98M-50.7%
Q4 FY2019CQ1 2019Mar 31, 2019$2.68M-64.7%
Q3 FY2019CQ4 2018Dec 31, 2018$4.08M-46.6%
Q2 FY2019CQ3 2018Sep 30, 2018$5.10M-35.8%
Q1 FY2019CQ2 2018Jun 30, 2018$6.04M-39.4%
Q4 FY2018CQ1 2018Mar 31, 2018$7.57M-31.1%
Q3 FY2018CQ4 2017Dec 31, 2017$7.64M-42.5%
Q2 FY2018CQ3 2017Sep 30, 2017$7.95M-36.8%
Q1 FY2018CQ2 2017Jun 30, 2017$9.96M–
Q4 FY2017CQ1 2017Mar 31, 2017$10.98M–
Q3 FY2017CQ4 2016Dec 31, 2016$13.28M–
Q2 FY2017CQ3 2016Sep 30, 2016$12.58M–

More Elite Pharmaceuticals figures

See a number that looks wrong?